Trial design
Breast Cancer
DUCTAL CARCINOMA IN SITU, DCIS, BREAST CANCER, BREAST DUCTAL CARCINOMA IN SITU
The study outline of the Taiwan Breast Cancer Consortium (TBCC)- Japan Academic Research Organization (ARO) is a prospective, international, open-label, randomized, non-inferiority trial. A flowchart of the TBCC-ARO DCIS trial is shown in Fig. Schematic diagram of the design of an international open-label randomized non-inferiority trial of whole breast radiotherapy versus low-dose tamoxifen for low-risk and estrogen receptor-positive breast ductal carcinoma in situ after breast conserving surgery. Abbreviations: DCIS, ductal carcinoma in situ; BCS, breast conserving surgery; SNP, single nucleotide polymorphism